Detalhe da pesquisa
1.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
Inglês
| MEDLINE | ID: mdl-29365309
2.
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Clin Infect Dis
; 69(10): 1657-1664, 2019 10 30.
Artigo
Inglês
| MEDLINE | ID: mdl-30923816
3.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology
; 67(2): 514-523, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28926120
4.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Hepatology
; 67(2): 505-513, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28865152
5.
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
J Med Virol
; 91(7): 1307-1312, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30840774
6.
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
J Hepatol
; 69(2): 293-300, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29551706
7.
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30061289
8.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29180522
9.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Antimicrob Agents Chemother
; 62(1)2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29084747
10.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28842997
11.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Ann Hepatol
; 17(6): 959-968, 2018 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-30600291
12.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28193664
13.
An interferon-free antiviral regimen for HCV after liver transplantation.
N Engl J Med
; 371(25): 2375-82, 2014 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-25386767
14.
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med
; 370(17): 1594-603, 2014 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-24720703
15.
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
N Engl J Med
; 370(3): 222-32, 2014 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-24428468
16.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med
; 370(17): 1604-14, 2014 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-24720679
17.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Antimicrob Agents Chemother
; 60(2): 1106-13, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26643326
18.
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet
; 385(9986): 2502-9, 2015 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-25837829
19.
Exploratory study of oral combination antiviral therapy for hepatitis C.
N Engl J Med
; 368(1): 45-53, 2013 Jan 03.
Artigo
Inglês
| MEDLINE | ID: mdl-23281975
20.
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Gastroenterology
; 149(4): 971-80.e1, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26170136